NewLink-Genentech deal could be worth more than $1bn

NewLink Genetics has been in the news recently for its experimental ebola vaccine, but the Ames, Iowa-based company's stock jumped 7.1% to $31.44 per share on 20 October based on a cancer immunotherapy deal with Genentech potentially worth more than $1bn.

NewLink Genetics has been in the news recently for its experimental ebola vaccine, but the Ames, Iowa-based company's stock jumped 7.1% to $31.44 per share on 20 October based on a cancer immunotherapy deal with Genentech potentially worth more than $1bn.

Genentech, a member of the Roche Group, will give NewLink $150m up front and could pay out $1bn-plus in milestone...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category